Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

BLTE

Belite Bio Inc ADR

Dec 13 • 04:00PM ET

62.34

Dollar change -1.03
Percentage change -1.63	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BIIB GILD MRNA BMY AMGN PFE LLY ABBV

| Held by: SPEM EWX APIE BBC GXC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.11	Insider Own	-	Shs Outstand	30.88M	Perf Week	-16.18%
Market Cap	1.93B	Forward P/E	-	EPS next Y	-0.90	Insider Trans	-	Shs Float	-	Perf Month	-24.19%
Income	-33.03M	PEG	-	EPS next Q	-0.33	Inst Own	0.47%	Short Float	-	Perf Quarter	27.82%
Sales	0.00M	P/S	-	EPS this Y	-0.42%	Inst Trans	-41.05%	Short Ratio	3.27	Perf Half Y	24.78%
Book/sh	3.63	P/B	17.16	EPS next Y	25.10%	ROA	-38.10%	Short Interest	0.23M	Perf Year	41.06%
Cash/sh	3.53	P/C	17.66	EPS next 5Y	-	ROE	-40.04%	52W Range	31.00 - 86.53	Perf YTD	36.26%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-29.44%	52W High	-27.96%	Beta	-1.63
Dividend TTM	-	Quick Ratio	24.76	Sales past 5Y	0.00%	Gross Margin	-	52W Low	101.06%	ATR (14)	5.03
Dividend Ex-Date	-	Current Ratio	24.76	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	41.08	Volatility	6.47% 7.40%
Employees	20	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	86.67
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-14.54%	Payout	-	Rel Volume	0.40	Prev Close	63.37
Sales Surprise	-	EPS Surprise	2.78%	Sales Q/Q	-	Earnings	Nov 12 BMO	Avg Volume	70.92K	Price	62.34
SMA20	-12.12%	SMA50	-7.81%	SMA200	22.02%	Trades		Volume	28,713	Change	-1.63%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Maxim Group	Buy	$60
Jul-28-23	Initiated	Cantor Fitzgerald	Overweight	$43
Jul-26-23	Initiated	SVB Securities	Outperform	$25
Aug-01-22	Initiated	H.C. Wainwright	Buy	$58
Jul-01-22	Initiated	The Benchmark Company	Buy	$57

Nov-27-24 03:00AM	Lin BioScience Receives U.S. FDA Fast Track Designation For LBS-007 (GlobeNewswire) +5.34%
Nov-12-24 01:00AM	Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Nov-05-24 08:00AM	Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-03-24 04:00PM	Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds (GlobeNewswire)
Oct-14-24 08:00AM	Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting (GlobeNewswire)
08:00AM	Loading…
Oct-08-24 08:00AM	Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit (GlobeNewswire) +5.93%
Sep-26-24 08:51AM	Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Sep-19-24 02:30AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-17-24 11:22AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024 (GlobeNewswire)
Sep-10-24 08:00AM	Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
Sep-03-24 08:00AM	Belite Bio to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Sep-01-24 08:00AM	Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer (GlobeNewswire)
Aug-09-24 09:52PM	BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 (InvestorPlace)
04:30PM	Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-08-24 08:00AM	Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.33%
07:10PM	Loading…
Aug-05-24 07:10PM	Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-08-24 08:00AM	Belite Bio to Present at the JonesHealthcare Seaside Summit (GlobeNewswire) +6.81%
Jun-12-24 02:55AM	Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan (GlobeNewswire)
May-14-24 08:00AM	Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference (GlobeNewswire)
07:53AM	BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 (InvestorPlace)
05:17AM	Belite Bio's Q1 Loss Narrows (MT Newswires)
May-13-24 09:50PM	Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-08-24 08:00AM	Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results (GlobeNewswire)
May-06-24 08:15AM	Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant (GlobeNewswire)
08:00AM	Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting (GlobeNewswire)
May-01-24 04:15PM	Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Apr-26-24 06:21AM	Belite Bio Unveils Plan to Offer 651,380 American Depository Shares (MT Newswires)
Apr-25-24 07:15PM	Belite Bio Announces $25 Million Registered Direct Offering (GlobeNewswire)
Apr-10-24 09:55AM	Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect? (Zacks)
08:00AM	Loading…
Mar-22-24 08:00AM	Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan (GlobeNewswire)
Mar-11-24 10:28PM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire) -12.47%
09:27PM	Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 08:00AM	Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-04-24 08:00AM	Belite Bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-07-24 08:00AM	Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-30-23 08:00AM	Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference (GlobeNewswire) +10.10%
Nov-20-23 08:00AM	Belite Bio to Participate in the BTIG Ophthalmology Day (GlobeNewswire)
Nov-13-23 08:15PM	Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Nov-10-23 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Nov-07-23 08:00AM	Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 04:00PM	Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023 (GlobeNewswire)
08:00AM	Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting (GlobeNewswire)
Nov-01-23 08:35AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts (GlobeNewswire) +5.04%
Oct-31-23 08:35PM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 (GlobeNewswire)
Oct-27-23 08:00AM	Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting (GlobeNewswire)
Aug-21-23 11:12AM	Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why (Zacks)
Aug-08-23 10:17PM	Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Aug-04-23 08:00AM	Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results (GlobeNewswire) +10.63%
Jul-31-23 07:57AM	Is Belite Bio, Inc (NASDAQ:BLTE) Worth US$24.1 Based On Its Intrinsic Value? (Simply Wall St.)
Jul-27-23 05:00PM	Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA (GlobeNewswire) +10.37% +17.27%
Jul-24-23 06:04AM	Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease (GlobeNewswire)
Jun-30-23 04:09PM	Why Shares of Belite Bio Soared This Week (Motley Fool)
May-31-23 12:22PM	Why Shares of Belite Bio Are Slumping Wednesday (Motley Fool) -31.09%
May-30-23 08:49PM	Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants (GlobeNewswire)
04:01PM	Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants (GlobeNewswire)
May-10-23 07:58PM	Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
03:33PM	Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 11:09AM	Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data (GlobeNewswire)
Apr-25-23 04:30PM	Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting (GlobeNewswire)
Apr-11-23 09:00AM	Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1 (GlobeNewswire)
Apr-08-23 09:02AM	We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow (Simply Wall St.)
Mar-31-23 07:03PM	Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
12:57PM	Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results (GlobeNewswire)
Jan-09-23 08:45AM	3 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Dec-08-22 05:14AM	2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023 (Motley Fool)
Nov-18-22 08:00AM	Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008) (GlobeNewswire)
Oct-20-22 08:00AM	Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data (GlobeNewswire)
Oct-03-22 04:07PM	Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today (Investor's Business Daily) -13.26%
Oct-01-22 07:03PM	Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022 (GlobeNewswire)
Sep-23-22 08:00AM	Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting (GlobeNewswire) -5.08%
Sep-16-22 08:00AM	Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China (GlobeNewswire) +9.17%
Aug-22-22 08:00AM	Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S. (GlobeNewswire) +18.92%
Aug-10-22 09:51PM	Belite Bio Reports First Half 2022 Operational Highlights and Financial Results (GlobeNewswire) +5.30%
Aug-01-22 04:10PM	Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results (GlobeNewswire)
02:36PM	'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst (Benzinga)
Jul-30-22 10:47AM	We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely (Simply Wall St.)
Jul-19-22 04:05PM	Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease (GlobeNewswire) +5.25% -22.17%
May-12-22 04:30PM	Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering (GlobeNewswire)
May-05-22 08:00AM	Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022 (GlobeNewswire) +15.16%
May-03-22 04:30PM	Belite Bio Announces Closing of $36 Million Initial Public Offering (GlobeNewswire) +30.78% +13.71%
06:50AM	Belite Bio Receives FDA Fast Track Designation For LBS-008 (GlobeNewswire)

Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Wei-Cheng Liaw	affiliate	Nov 20 '24	Proposed Sale	82.53	5,999	495,097	Nov 20 06:25 PM
Nathan Mata	Affiliate	Nov 19 '24	Proposed Sale	82.34	30,000	2,470,200	Nov 19 06:17 PM
Yu-Hsin Lin	CEO, Chairman	Oct 03 '24	Proposed Sale	48.00	40,000	1,920,000	Oct 03 08:50 PM
Hao-Yuan Chuang	Officer, Director	Oct 03 '24	Proposed Sale	48.00	40,000	1,920,000	Oct 03 08:48 PM
Wei-Cheng Liaw	affiliate	Sep 20 '24	Proposed Sale	48.14	6,500	312,910	Sep 20 12:40 PM
Wan Shan Chen	affiliate	Sep 04 '24	Proposed Sale	48.10	6,650	319,865	Sep 04 12:29 PM
Nathan Mata	affiliate	Aug 16 '24	Proposed Sale	500.00	30,000	15,000,000	Aug 16 06:24 PM
Hao-Yuan Chuang	Officer, Director	Aug 14 '24	Proposed Sale	49.32	100,000	4,932,000	Aug 14 04:32 PM
Yu-Hsin Lin	CEO, Chairman	Aug 14 '24	Proposed Sale	49.32	100,000	4,932,000	Aug 14 04:30 PM
Chiu, Ching Chen	affiliate	Aug 14 '24	Proposed Sale	49.84	34,568	1,722,869	Aug 14 02:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLTE

Belite Bio Inc ADR

Upgrade your FINVIZ experience